Higher adherence to inhaled corticosteroids is not associated with a reduction in asthma exacerbations within Real-Life Historical Cohort Study.

Alberto Papi, MD a, Dermot Ryan, FRCGP b,c, Joan B Soriano, M.D., Ph.D., FERS, FCCP d, Henry Chrystyn, BPharm, MSc, FRPharmS, PhD e,f, Leif Bjermer, MD g, Roberto Rodríguez-Roisin, MD, PhD, FRCP (Edinburgh) and FERS h, Myrna B Dolovich, B.Eng, P. Eng.i, Mark Harris, BA (Hons) i, Lucy Wood, MA (Cantab), MSc e, Maria Batsiou, MSc, GradStat e, Susannah I Thornhill, PhD e, David B Price, FRCGP e,k

a Department of Respiratory Medicine, University of Ferrara, Ferrara, Italy
b Allergy and Respiratory Research Group, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK
c Optimum Patient Care, Cambridge, UK
d Instituto de Investigación Hospital Universitario de la Princesa (IISP), Universidad Autónoma de Madrid, Madrid, Spain
e Observational and Pragmatic Research Institute, Singapore
f Inhalation Consultancy Ltd, Yeadon, Leeds, LS19 7SP
g Respiratory Medicine & Allergology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
h Servei de Pneumologia (Institut del Tòrax), Hospital Clínic-IDIBAPS-CIBERES, Universitat de Barcelona, Barcelona, Spain
i Department of Medicine, Respirology, McMaster University, Hamilton, Ontario, Canada
j Optimum Patient Care, Cambridge, UK
k Academic Primary Care, University of Aberdeen, UK

Corresponding author. Prof David B Price, Academic Primary Care, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, UK AB25 2ZD
Tel: +65 6802 9724; E-mail: dprice@opri.sg
Postal addresses and email addresses of authors

Alberto Papi

Research Centre on Asthma and COPD, Department of Medical Sciences, University of Ferrara, Ferrara, Italy

Postal address: Section of Respiratory Medicine, University of Ferrara, Via Rampari di San Rocco, 27, 44121 Ferrara, Italy

Email address: ppa@unife.it

Dermot Ryan

Allergy and Respiratory Research Group, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK

Optimum Patient Care, Cambridge, UK

Postal address: Allergy and Respiratory Research Group, Usher Institute for Population Health Sciences & Informatics, The University of Edinburgh, College of Medicine and Veterinary Medicine, Edinburgh Medical School, Doorway 3, Teviot Place, Edinburgh EH8 9AG, UK

Email address: dermotryan@doctors.org.uk

Joan B Soriano

Instituto de Investigación Hospital Universitario de la Princesa (IISP), Universidad Autónoma de Madrid, Madrid, Spain

Postal address: Instituto de Investigación Hospital Universitario de la Princesa (IISP), Universidad Autónoma de Madrid, Diego de León 62, 28030 Madrid, Spain

Email address: jbsoriano2@gmail.com

Henry Chrystyn
Leif Bjermer

Respiratory Medicine & Allergology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden

Postal address: Respiratory Medicine & Allergology, Department of Clinical Sciences Lund, Biomedical Center B14, Tornavägen 10, SE 221 84 Lund, Sweden

Email address: leif.bjermer@med.lu.se

Roberto Rodríguez-Roisin

Universitat de Barcelona, Hospital Clinic-IDIBAPS, Barcelona, Spain

Postal address: Hospital Clínic, Villarroel 170, 08036-Barcelona, Spain

Email address: rororo@clinic.cat

Myrna B Dolovich

Department of Medicine, Respirology, McMaster University, Hamilton, Ontario, Canada

Postal address: St Joseph’s Healthcare, McMaster University, Department of Medicine, 50 Charlton Ave East, FIRH Room T2135, Hamilton, ON, Canada L8N 4A6

Email address: mdolovic@mcmaster.ca

Mark Harris

Optimum Patient Care, Cambridge, UK

Postal address: Optimum Patient Care, Units 5 and 6, The Old Granary, Westwick, Oakington, Cambridge, CB24 3AR, UK
Email address: markpharris1@gmail.com

Lucy Wood
- Observational and Pragmatic Research Institute, Singapore

  Postal address: Observational and Pragmatic Research Institute, 60 Paya Lebar Road, Paya Lebar Square, Level 5, Unit 33 & 34, Singapore 409051

Email address: lucyiswood@gmail.com

Maria Batsiou
- Observational and Pragmatic Research Institute, Singapore

  Postal address: Observational and Pragmatic Research Institute, 60 Paya Lebar Road, Paya Lebar Square, Level 5, Unit 33 & 34, Singapore 409051

Email address: m.batsiou@yahoo.gr

Susannah I Thornhill
- Observational and Pragmatic Research Institute, Singapore

  Postal address: Observational and Pragmatic Research Institute, 60 Paya Lebar Road, Paya Lebar Square, Level 5, Unit 33 & 34, Singapore 409051

Email address: suzythornhill@yahoo.co.uk

David B Price
- Observational and Pragmatic Research Institute, Singapore
- Academic Primary Care, University of Aberdeen, Aberdeen, UK

  Postal address: Academic Primary Care, University of Aberdeen, Polwarth Building, Forsterhill, Aberdeen, UK AB25 2ZD

  Tel: +65 6802 9724

Email address: dprice@opri.sg
What is already known about this topic? Non-adherence to inhaled corticosteroid (ICS) therapy and elevated blood eosinophil levels are both associated with an increased risk of exacerbations in patients with asthma.

What does this article add to our knowledge? Using combined routine clinical and patient-reported data we provide evidence that adherence to refill prescriptions for ICS therapy in patients with asthma with elevated blood eosinophils is not associated with a decrease in asthma exacerbations.

How does this study impact our current management guidelines? This study supports the requirement of additional therapy for patients with elevated blood eosinophil levels that continue to experience frequent asthma exacerbations, despite adherence to ICS.
Abstract

Background: Patients with asthma and elevated blood eosinophils are at increased risk of severe exacerbations. Management of these patients should consider non-adherence to inhaled corticosteroid (ICS) therapy as a factor for increased exacerbation risk.

Objective: To investigate whether poor adherence to ICS therapy explains the occurrence of asthma exacerbations in patients with elevated blood eosinophil levels.

Methods: This historical cohort study identified patients within the Optimum Patient Care Research Database, aged ≥18 years, at Global Initiative for Asthma (GINA) steps 3 or 4, with ≥2 ICS prescriptions during the year prior to clinical review. Patient characteristics and adherence (based on prescription refills and patient self-report) for ICS therapy were analysed for those with elevated (>400 cells/µL) or normal (≤400 cells/µL) blood eosinophils.

Results: We studied 7,195 patients (66% female, mean age 60 years) with median eosinophil count of 200 cells/µL and found 81% to be non-fully adherent to ICS therapy. 1,031 patients (14%) had elevated blood eosinophil counts (58% female, mean age 60 years), 83% of whom were non-fully adherent to ICS. An increased proportion of adherent patients in the elevated blood eosinophil group had ≥2 exacerbations (14.0% vs 7.2%; p=0.003) and uncontrolled asthma (73% vs 60.8%; p=0.004) as compared to non-fully adherent patients.

Conclusions: Approximately one in seven patients had elevated eosinophils. Adherence to ICS therapy was not associated with decreased exacerbations for these patients. Additional therapy should be considered for these patients, such as biologics, which have been previously shown to improve control in severe uncontrolled eosinophilic asthma.

Keywords: adherence; asthma control; eosinophils; asthma exacerbations; inhaled corticosteroids; severe asthma

Abbreviations:
ACO: Asthma-COPD Overlap
COPD: Chronic Obstructive Pulmonary Disease
ENCePP: European Network of Centres for Pharmacoepidemiology and Pharmacovigilance
REC: Research Ethics Committee
FeNO: Fraction of exhaled Nitric Oxide
GINA: Global Initiative for Asthma
ICS: Inhaled Corticosteroid
iHARP: initiative Helping Asthma in Real People
IQR: Interquartile range
LABA = Long-acting β-agonist
LAMA = long-acting muscarinic antagonist
LTRA = leukotriene receptor antagonist
MARS: Medication Adherence Rating Scale
MPR: Medication Possession Ratio
OPCRD: Optimum Patient Care Research Database
QOF: Quality and Outcomes Framework
SABA = short-acting β-agonist
SAMA = short-acting muscarinic antagonist
SD: Standard Deviation

Metrics information:

Date: 5th March 2018
Abstract word count: 250 words
Text word count: 4385 words
Number of references: 53 references
Number of tables and figures: 2 tables and 4 figures
Online supplement: yes, with 5 e-Tables
INTRODUCTION

The complex interrelationship between asthma control, exacerbation risk, blood eosinophil counts and asthma treatment, has been the subject of recent studies. In randomised controlled trials of severe asthma, blood eosinophil counts were associated with increased exacerbation risk. In real world studies, patients with asthma and blood eosinophil counts greater than 400 cells/μL similarly experienced more exacerbations, coupled with poorer asthma control.

The Global Initiative for Asthma (GINA) describes steps to maintain asthma control while reducing severe exacerbation risk. An observational database study showed that patients with blood eosinophil counts greater than 400 cells/μL were more likely to be on higher therapeutic steps (steps 3 or 4) of the GINA management approach to control and risk. Blood eosinophil counts may therefore aid clinicians to establish GINA-based asthma management.

Non-adherence to prescribed medication is also an important risk factor for exacerbations, including asthma-related hospitalisations and death. Achievement of long-term asthma control is more likely when patients adhere to prescribed therapy, resulting in a significant reduction in the risk of death. However, patients may still remain with uncontrolled symptoms and at risk of exacerbation despite good adherence to prescription for inhaled corticosteroid (ICS).

We hypothesised that there exists a population of patients with eosinophilic asthma, a common asthma phenotype characterised by elevated blood eosinophil counts, are still at risk of exacerbation despite good adherence to prescribed ICS treatment. This study aimed to identify and quantify the population of patients with asthma with elevated blood eosinophil levels, and to investigate whether poor adherence to ICS therapy explains the occurrence of exacerbations and poor asthma control in this subset of patients.
METHODS

This was a historical cohort study, using linked routine clinical and patient-reported data. The study period consisted of a baseline year for patient characterisation and confounder definition, followed by a clinical review (questionnaire collection) for outcome evaluation (Figure 1). An independent steering committee was involved in all phases of the development of study design, review of analyses, and interpretation of results. The study protocol is registered with the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCEPP) (ENCEPP/SDPP/11512) and was conducted in accordance with the ENCePP Code of Conduct.

Data sources

Data were extracted from the Optimum Patient Care Research Database (OPCRD) and the initiative Helping Asthma in Real People (iHARP) database.

The OPCRD (www.opcrd.co.uk) is a quality-controlled research database containing fully-anonymous, longitudinal, routinely collected electronic medical record data and patient-reported questionnaire data from over 600 primary care practices across England, Scotland, Wales, and Northern Ireland. At the time of writing, the database encompassed more than 4.5 million patients from the United Kingdom (UK) population. The OPCRD is approved by the Health Research Authority of the UK National Health Service for clinical research use (Research Ethics Committee [REC] reference: 15/EM/0150).

The iHARP database is a global initiative that conducts thorough asthma review clinics according to asthma guidelines, recording parameters including inhaler technique and spirometry. The database currently comprises approximately 5,000 patients from the UK, the Netherlands, Norway, Spain, Italy, Sweden, Australia and France. UK patients who met all iHARP eligibility criteria (diagnosed with asthma, are receiving fixed dose combination ICS/LABA, are aged ≥18years, and are at GINA step 3 or 4 during iHARP review), ascertained from the OPCRD population, were invited for an iHARP review. To optimise the number of
study patients and the evaluation of adherence, iHARP and OPCRD questionnaire data were combined in one dataset. Duplicate patients were removed.

**Study population**

The study population included adult patients, aged ≥18 years, with at least 1 year of continuous valid data prior to the date of clinical review and with a prior diagnosis of asthma any time before review based on the recorded Quality and Outcomes Framework (QOF) Read codes, the clinical coding system within UK’s general practice for asthma. Presence of QOF read codes indicate physician diagnosed asthma, however the criteria on which diagnosis had been made was not accessible. Patients were receiving GINA step 3 or 4 asthma management, as determined on the date of clinical review using GINA criteria (2010-2012) for asthma control and risk (*Table E1*), had ≥2 ICS (fluticasone propionate-equivalent units) prescriptions during the baseline year, and had a valid blood eosinophil count recorded at any time prior to clinical review (*Figure 1*). Patients with a diagnosis of chronic obstructive pulmonary disease (COPD; QOF Read codes), or who were prescribed either acute oral corticosteroids in the 4 weeks prior to eosinophil count or long-term systemic or maintenance oral corticosteroids for asthma, were excluded. Eligible patients were divided into two groups according to blood eosinophil count of either ≤400 cells/μL (normal blood eosinophil count) or >400 cells/μL (elevated blood eosinophil count). A value of ≤400 cells/μL was selected *a priori* as this is the upper limit of the published normal blood eosinophil count range (0–400 cells/μL) in UK clinical practice. 17 The last valid count before the date of clinical review was used to stratify patients into elevated and normal blood eosinophil cohorts.

**Measures of Adherence**

Adherence to ICS therapy was assessed from combined routine and questionnaire data. Routine data was based on the medication possession ratio (MPR), defined as the number of ICS prescriptions issued divided by the number of ICS prescriptions expected
(based on prescribed ICS dose). An MPR of >80% was considered to be adherent to prescribed ICS therapy. Although a wide variety of cut-off values to define medication adherence have been used in the respiratory literature,\textsuperscript{18} a cut-off of >80% is the arbitrary standard threshold used.\textsuperscript{10,19-23} Patient-reported adherence was assessed using a 6-point (never, rarely, sometimes, regularly, often and always) Medication Adherence Rating Scale (MARS), consisting of 5 questions on controller inhaler usage.\textsuperscript{24} Patients were considered to be adherent if they had good adherence score across the 5 MARS questions, as well as an MPR of >80%. More details are available in the supplementary methods.

**Clinical Endpoints**

The clinical outcomes of this study were the number of severe asthma exacerbations and asthma control. The number of severe asthma exacerbations was defined based on the American Thoracic Society (ATS)/European Respiratory Society (ERS) Task Force definition\textsuperscript{25} to include asthma-related hospital admissions, accident and emergency attendances, or prescription for acute courses of oral corticosteroids. An asthma-related admission was defined as any definite asthma-related hospitalisation or a generic hospitalisation recorded on the same day as a lower-respiratory consultation. Acute oral corticosteroid use associated with asthma exacerbation therapy was defined as all courses that were not maintenance therapy, and/or all courses where dosing instructions suggested exacerbation therapy based on the prescription strength or frequency. Asthma control was ascertained based on a composite measure of risk-domain asthma control and overall asthma control. Risk-domain asthma control was defined as the absence of asthma-related hospital admissions, accident and emergency attendances, out-patient attendances, antibiotics prescribed alongside a lower-respiratory consultation, or prescription for acute courses of oral corticosteroids. Overall asthma control was defined as achieved risk-domain asthma control and average daily dose of ≤200µg salbutamol or ≤500µg terbutaline. Questionnaire and routine data were combined and used to assess adherence, while routine data alone was used to assess all other variables. Further details on the outcomes can be found in the supplementary data.
Statistical analyses

The main analysis included patients with eosinophil counts recorded at any time prior to the date of questionnaire collection. All statistical analyses were conducted using SAS version 9.4 (SAS Institute, North Carolina, USA). Statistical evidence was determined if P-values were less than 0.05.

Summary statistics were calculated for patient demographics and baseline characteristics, both overall, and by elevated and normal blood eosinophil cohorts. For continuous variables either the mean and standard deviation (SD) or the median and interquartile range (IQR) were calculated. For categorical variables, the frequency and percentage of observed levels were calculated for the sample with non-missing observations. Patient demographic and baseline characteristics were compared between the elevated and normal blood eosinophil cohorts using the Chi-square test, t-test or Mann-Whitney U test, where appropriate.

Primary outcome analysis

The percentage of patients with 0, 1 or 2+ exacerbations, and the percentage of patients with controlled or uncontrolled asthma were compared between adherent and non-fully adherent patients within each blood eosinophil count group. Multinomial and binomial logistic regression were performed to compare exacerbations and asthma control respectively, adjusting for age, smoking status, bronchiectasis and active rhinitis.

Sensitivity analysis

Two sensitivity analyses were planned a priori. The primary outcome analysis was repeated for the following groups of patients and for the exacerbations outcome only:

1. Patients with blood eosinophil counts recorded within 1 year from the date of questionnaire collection

2. Patients with eosinophil counts recorded ever prior to questionnaire collection, where the cut-off for elevated eosinophil count was set a priori at >300 cells/µL
RESULTS

Baseline demographic and clinical characteristics

The total iHARP/OPCRD population at the time of study initiation was 30,634 patients. After applying all inclusion and exclusion criteria, the final study population consisted of 7195 patients, 1119 from iHARP and 6076 from OPCRD (Figure 2). Baseline characteristics of patients from both databases were similar apart from older patients in the OPCRD (mean age: 61.2 years vs 54.8 years) and more current (38.1% vs 10.7%), but fewer ex-smokers (7.1% vs 34.0%) in the OPCRD compared to iHARP. Patients had a mean age of 60 years, 66% were female, 72% were classified as overweight/obese and 45% were current/former smokers (Table 1). Patients had a median eosinophil count of 200 cells/µL (IQR: 120-320 cells/µL) (Table E3). During the baseline year, 22% received acute courses of oral corticosteroids with a respiratory consultation, and the majority were prescribed multiple respiratory medications.

Overall, 1,031 of the 7,195 patients (14%) had elevated blood eosinophil counts (>400 cells/µL). Compared with patients who had blood eosinophil counts of ≤400 cells/µL, patients with elevated blood eosinophils were more likely to be male (42% vs 33%, p<0.001) and a smaller proportion were obese (29.5% vs 37.0%) (Table 1). Both the elevated and normal blood eosinophil cohorts were reasonably well balanced in terms of clinical variables and prescribed medication during the baseline year. No significant differences were observed between the groups in ICS daily dose or courses of oral corticosteroids; however, more patients with elevated blood eosinophils were treated with ICS+LABA (or LAMA) (79.6%) compared with those with blood eosinophil counts ≤400 cells/µL (76.1%) (Table 1). In terms of comorbidities, patients with elevated blood eosinophil counts had higher prevalence of active rhinitis (p=0.043) and eczema (p=0.003), and lower prevalence of hypertension (p=0.004), compared to patients within the normal blood eosinophil cohort (Table 1).

A breakdown of blood eosinophil counts for both cohorts, in terms of average daily dose of ICS, can be seen in Table E2. Approximately 80% of patients in both groups had eosinophil counts measured within 3 years prior to the questionnaire collection (Table E3).
Finally, only 19.4% patients studied had good adherence to ICS therapy (Table 2). Significantly more adherent patients were older (p=0.001), never smoked (p=0.010), and had co-morbid rhinitis (p<0.001), bronchiectasis (p<0.001), and oral thrush (p=0.035). There were also significant differences in medication profile (p<0.001) between adherence groups. However, there was no significant difference in the proportion of patients with blood eosinophil count >400 cells/µL (p=0.067) between patients who were adherent and patients who were not fully adherent to ICS therapy.

**Primary outcome**

The percentage of patients with 0, 1 or 2+ exacerbations in each blood eosinophil cohort, stratified by adherence to ICS therapy, is shown in Figure 3. The distribution of exacerbations differed significantly across adherence and eosinophil level groups, with the adherent patients in the elevated eosinophil group having the highest proportion of patients (14.0%) experiencing 2 or more exacerbations. Similar results were obtained in both sensitivity analyses (Tables E4 and E5).

The proportion of patients defined as having controlled asthma was also found to differ significantly between adherence groups; 73% of adherent patients in the elevated blood eosinophil cohort (>400 cells/µL) were found to have uncontrolled disease compared to 61% of patients non-fully adherent to ICS treatment (p=0.004) (Figure 4).

**DISCUSSION**

This is the first study to use routine clinical data to assess associations between adherence to ICS therapy, elevated blood eosinophil counts and poor asthma control. In this novel, historical cohort study of over 7,000 patients with asthma and a clinically valid recorded blood eosinophil count, 14% had elevated blood eosinophils (>400 cells/µL). Within this group, 178 (17%) were adherent to ICS, of which 25 (14%) experienced ≥2 exacerbations and 130 (73%) remained uncontrolled.

For patients with elevated blood eosinophils, the distribution of both exacerbations and
asthma control differed significantly between the ICS adherence groups. A higher proportion of adherent patients had ≥2 exacerbations (14% versus 7%) and uncontrolled asthma (73% versus 61%) compared to non-fully adherent patients. A sensitivity analysis with a cut-off for high blood eosinophils of >300 eosinophils/μL demonstrated similar results, with an increased proportion of adherent patients experiencing severe asthma exacerbations during the baseline year (Table E5, p=0.017 for 1 and p=0.022 for ≥2 exacerbations). We also analysed the relationship between adherence and exacerbation or symptom control in those with lower blood eosinophil counts, based on results from other studies that lower eosinophil group patients had worse response to ICS\textsuperscript{27,28}. In the current observational study however, the relationship between adherence and the clinical outcomes was similar between the high and low eosinophil groups. There was also no significant statistical interaction between adherence and eosinophil group (result not shown).

Differences in average daily ICS dose at baseline for elevated versus normal blood eosinophil counts were non-significant (median, 247 μg/day [IQR, 137-427 μg/day] vs 263 μg/day [IQR 164-438 μg/day] fluticasone equivalent; p=0.063) and not clinically relevant. A dose–response effect of ICS on the reduction of blood eosinophil count for doses of up to 800 μg/day (beclomethasone-equivalent) has been reported elsewhere\textsuperscript{29}. Dose–response relationships between prescribed ICS and elevated blood eosinophil counts in patients with severe asthma should therefore be assessed in future studies\textsuperscript{30}.

One third of our study population prescribed medication within GINA steps 3 and 4 were current smokers, with more than 10% former smokers. Previous studies have reported that smoking hinders response to ICS treatment\textsuperscript{31,32}, and smoking status is therefore likely to confound the relationship between adherence to ICS treatment and symptom outcomes. We thus adjusted for smoking status in the analysis of the relationship between adherence and asthma outcomes. Current and ex-smokers were found to be at significantly lower odds of having their asthma symptoms controlled than never smokers in the regression model (data not shown). This serves as a reminder for the requirement of continued efforts to offer smoking cessation to all respiratory patients.
Of note, 29% of patients with asthma included in this study received antibiotics during a respiratory consultation in the baseline year; it is unknown whether these prescriptions were clinically indicated or necessary. Although the signs and symptoms of an asthma exacerbation can be non-specific, antibiotics should only be prescribed for patients with asthma when a bacterial infection is suspected; empirical or preventative use is not endorsed. This is a further call to strengthen government policy on the reduction of the unnecessary use of antibiotics to prevent side effects and thus avoid antimicrobial resistance.  

In our study, patients with severe asthma and an elevated blood eosinophil count experienced frequent severe asthma exacerbations, despite evidence of adherence to refills for prescribed ICS therapy. This observation is in agreement with a previous retrospective study in which asthma patients adherent to their controller therapy were not at lower risk for symptom exacerbation. Whilst this may indicate that a step-up in inhaled therapy is required for these patients, more than half of whom are on low-to-medium dose ICS treatment (≤320 µg/day), it is likely that additional therapy, including the consideration of biologics, is needed. 18% of patients within the elevated eosinophil cohort received an ICS daily dose of more than 500 µg; this group of patients in particular may benefit from therapies specifically targeting eosinophilic airway inflammation, such as novel monoclonal antibodies, due to non-responsiveness to ICS therapy.  

Blood eosinophil count is a useful biomarker for T2 profile asthma, but not all patients with asthma have a T2 profile. A study of adult-onset asthma found that increased blood neutrophil count was associated with disease severity. Thus, blood neutrophil count would be an informative addition to further studies of this type to examine exacerbation risk.  

Compared with the assessment of eosinophil counts in sputum, which is impractical in non-specialised clinics, simpler and less invasive clinical tests, such as peripheral blood eosinophil count or fraction of exhaled nitric oxide (FeNO), may be more clinically feasible for assessing exacerbation risk and control. However, although there is a correlation between blood eosinophilia and FeNO, these biomarkers may be measuring differing inflammatory domains. Recent evidence suggests that blood eosinophils alone may not be sufficient to
estimate lung inflammation; further research is needed to understand the dynamics of this relationship in routine clinical practice.41

Poor inhaler technique has been previously reported to be correlated with poor asthma control and asthma exacerbation and is frequently encountered42,43. Thus, it is likely that poor inhaler technique may have accounted for some of the poor asthma control and exacerbations observed within our adherent subjects. However, there is little to indicate differences in inhaler technique between compliant and non-compliant patients. This stresses the need for training and assessment of proper inhalation technique to assist in controlling asthma symptoms and exacerbations.

Strengths of this study include the large sample size of patients with physician-diagnosed asthma and valid eosinophil readings. In addition, the study inclusion and exclusion criteria minimised potential confounding factors such as other asthma therapies, and the study identified patients prescribed ICS therapy from two large, well-described databases. To ensure that all potentially relevant variables for characterising patients were included and that the key outcomes of interest could be evaluated, the statistical analysis plan, study population and outcomes were all determined prior to any analyses.

However, there are potential limitations which are worth considering. This study aimed to represent real-life asthma care, but the study population might not be fully representative of the general UK asthma population. The proportion of patients with a Read code for physician-diagnosed asthma, who actually have asthma, is unknown.44,45 Patients diagnosed with other chronic respiratory diseases, such as COPD and asthma-COPD overlap (ACO) syndrome, were excluded; these reportedly occur in 15–20% of patients with asthma, while their prevalence in some populations may be even higher.46 Patients with features of both asthma and COPD often have frequent respiratory exacerbations;47 therefore, a similar study conducted using the identical databases and patient-reported data is needed to assess both asthma and COPD.

Adherence to ICS therapy was based on the medication possession ratio; however, it is not possible to determine whether the prescriptions for ICS were filled and taken by the
patient. In addition, the higher proportion of adherent patients in the more severe outcome
groups may conversely be a result of patients with more severe symptoms being more
adherent to their treatment. The MARS questionnaire was included in this study as a measure
of patient reported adherence. However, patient self-reported adherence is known to be prone
to inaccurate reporting by patients, either involuntarily (recall error) or voluntarily (over-
reporting adherence to avoid negative feedback from healthcare providers)\(^{48}\). This study
utilised both medication dispensation measure and patient self-report, via questionnaire, to
circumvent the weaknesses of each measure of adherence for a more accurate capture of
patient medication consumption.

Given the observational nature of our research, reasons for the timing of venepuncture
to determine eosinophil count and/or any other blood variable are unknown and cannot be
formally interpreted here. Eosinophil count is not a routinely conducted clinical procedure in
asthma management, and thus any eosinophilic measurement taken any time prior to the
index date (usually recorded as part of a Full Blood Count or Complete Blood Count, drawn
for other purposes) was included in this study to obtain a sufficiently large patient sample size.
Only 53% of the patients in the current study had their eosinophils measured within a year
before questionnaire collection (Supplementary Table E3). However, sensitivity analysis in
patients with eosinophil readings taken within 1 year from the index date showed similar
results (Supplementary Table E4). Additionally, a recent publication utilising OPCRD patient
records showed eosinophilic counts to be relatively stable over a period of one year\(^{49}\).

Lastly, it is possible that there are other potential confounders not currently taken into
account, which could provide an alternate explanation for the results of this study. In the
current study, adherence was assessed in the same period with asthma outcome measures.
Thus, it is not possible to determine the direction of causation between adherence and the
heightened number of exacerbation and uncontrolled symptoms. The Ascertaining Barriers to
Compliance (ABC) taxonomy of adherence subdivides the traditional single act of medication
adherence into separate acts of initiation, implementation, and persistence.\(^{50}\) Future studies
could therefore compare relationships among prescribed medications, asthma control, and
the different temporal stages of adherence.

It is widely believed in respiratory medicine that patients with severe or uncontrolled
asthma are poorly adherent to prescribed therapy.\textsuperscript{5,51} Contrarily, this study demonstrates that
adherence rate to treatment was not lower among patients with more severe symptoms.
Moreover, patients with elevated blood eosinophil levels who are non-responsive to ICS
therapy seem to constitute a higher proportion than previously suggested in the respiratory
literature.\textsuperscript{5,35}

**CONCLUSIONS**

One in seven patients in this study had elevated blood eosinophil counts; adherence
to ICS therapy in these patients was not associated with better clinical outcomes. There exists
a group of patients with asthma who are adherent with refill prescriptions to ICS therapy that
still experience frequent exacerbations. This was also observed in patients with an elevated
blood eosinophil level, which is usually indicative of better ICS responsiveness. Whilst it may
be appropriate to increase inhaled therapy for those on lower doses of ICS, it is likely that
additional treatment targeting other biological pathways apart from eosinophils may be
required for these patients to achieve disease control. Among the considerations are
interleukin suppressors such as anti-IL5 and other biologic therapies, which have been
previously shown to reduce asthma exacerbation\textsuperscript{52,53} and improve asthma control\textsuperscript{53} in patients
with elevated blood eosinophil levels.

**ACKNOWLEDGEMENTS**

This study was conducted by the Observational and Pragmatic Research Institute Pte Ltd, in
collaboration with the Respiratory Effectiveness Group (REG) and with institutional support
from Teva Pharmaceuticals Europe B.V. The authors would like to thank Annabel Allison and
Marcus Ngantcha for their assistance with analysis.
CONFLICT OF INTEREST DISCLOSURES

AP has received grants, personal fees and non-financial support from AstraZeneca, Chiesi Farmaceutici, GlaxoSmithKline, Boehringer Ingelheim, Merck Sharp & Dohme, Menarini, Novartis, Zambon, TEVA, Pfizer, Takeda, and Mundipharma.

DR In the last three years DR has received Consultancy fees from TEVA, Chiesi, AstraZeneca, Novartis, Boehringer Ingelheim, and has spoken on behalf of AstraZeneca and TEVA and MEDA.

JBS has received pharmaceutical company grants from GSK in 2011 and Chiesi in 2012 via CIMERA, his former home institution, and from Linde via Hospital Universitario de La Princesa in 2014 and 2015; and participated in speaking activities, advisory committees and consultancies during the period 2011–2016 sponsored by Almirall, AstraZeneca, Boehringer-Ingelheim, Chiesi, ERS, GEBRO, Grifols, GSK, Linde, Lipopharma, Mundipharma, Novartis, Pfizer, RiRL, Rovi, SEPAR, Takeda, and Teva.

HC has no shares in any pharmaceutical companies. He has received sponsorship to carry out studies, together with Board Membership, consultant agreements and honoraria for presentation, from several pharmaceutical companies that market inhaled products. These include Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Innovata Biomed, Meda, Napp Pharmaceuticals, Mundipharma, NorPharma, Norvartis, Orion, Sanofi, Teva, Truddell Medical International, UCB, and Zentiva. Research sponsorship has also been received from grant awarding bodies (EPSRC and MRC). He is the owner of Inhalation Consultancy Ltd. He is also an employee at Observational and Pragmatic Research Institute Pte Ltd, which conducted this study, with institutional support from Teva Pharmaceuticals Europe B.V., and has conducted paid research in respiratory disease on behalf of the following other organizations: UK National Health Service, British Lung Foundation, Aerocrine, AKL Research and Development Ltd, AstraZeneca, Boehringer Ingelheim,
Chiesi, Meda, Mundipharma, Napp, Novartis, Pfizer, Respiratory Effectiveness Group, Takeda, Teva Pharmaceuticals, Theravance, and Zentiva.

LB has received fees over the past three years for speaking or participating in advisory boards for Aerocrine, Arsonette, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mundipharma, Novartis, Sandoz, Sanofi, Takeda and Teva.

RRR has received personal fees from AstraZeneca, Boehringer Ingelheim, Pearl Therapeutics, TEVA, Menarini, and Novartis; and grants from Menarini.

MBD is on an Advisory Board of Teva Pharmaceuticals and has received a research grant from Boehringer Ingelheim, Canada.

MH was an employee of Optimum Patient Care at the time of the study.

LW, MB, and SIT were employees at the time of the study. Observational and Pragmatic Research Institute Pte Ltd conducted this study, with institutional support from Teva Pharmaceuticals Europe B.V., and has conducted paid research in respiratory disease on behalf of the following organizations: UK National Health Service, British Lung Foundation, Aerocrine, AKL Research and Development Ltd, AstraZeneca, Boehringer Ingelheim, Chiesi, Meda, Mundipharma, Napp, Novartis, Pfizer, Respiratory Effectiveness Group, Takeda, Teva Pharmaceuticals, Theravance, and Zentiva.

DBP has board membership with Aerocrine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Mundipharma, Napp, Novartis, and Teva Pharmaceuticals; consultancy agreements with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, and Theravance; grants and unrestricted funding for investigator-initiated studies (conducted
through Observational and Pragmatic Research Institute Pte Ltd) from Aerocrine, AKL Research and Development Ltd, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Mylan, Mundipharma, Napp, Novartis, Pfizer, Respiratory Effectiveness Group, Teva Pharmaceuticals, Theravance, UK National Health Service, Zentiva; payment for lectures/speaking engagements from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Merck, Mundipharma, Novartis, Pfizer, Skyepharma, and Teva Pharmaceuticals; payment for manuscript preparation from Mundipharma and Teva Pharmaceuticals; payment for the development of educational materials from Mundipharma and Novartis; payment for travel/accommodation/meeting expenses from Aerocrine, AstraZeneca, Boehringer Ingelheim, Mundipharma, Napp, Novartis, and Teva Pharmaceuticals; funding for patient enrolment or completion of research from Chiesi, Novartis, Teva Pharmaceuticals, and Zentiva; stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia, Singapore, and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); and is peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme, and Health Technology Assessment.
### Table 1: Baseline demographic and clinical characteristics in patients with asthma with elevated versus normal eosinophil counts

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Overall population (n=7195)</th>
<th>Blood eosinophil count</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean (SD)</td>
<td>&gt;400 cells/µL (n=1031)</td>
<td>≤400 cells/µL (n=6164)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>60.2 (15.1)</td>
<td>59.6 (15.8)</td>
<td>60.3 (15.0)</td>
</tr>
<tr>
<td>Sex</td>
<td>Male</td>
<td>2476 (34.4)</td>
<td>433 (42.0)</td>
</tr>
<tr>
<td></td>
<td>Underweight</td>
<td>81 (1.1)</td>
<td>13 (1.3)</td>
</tr>
<tr>
<td>Body Mass Index (BMI)</td>
<td>Normal</td>
<td>1897 (26.8)</td>
<td>304 (30.1)</td>
</tr>
<tr>
<td></td>
<td>Overweight</td>
<td>2565 (36.2)</td>
<td>396 (39.2)</td>
</tr>
<tr>
<td></td>
<td>Obese</td>
<td>2549 (35.9)</td>
<td>298 (29.5)</td>
</tr>
<tr>
<td>Smoking status</td>
<td>Non-missing</td>
<td>6953 (96.6)</td>
<td>999 (96.9)</td>
</tr>
<tr>
<td></td>
<td>Never</td>
<td>3815 (54.9)</td>
<td>573 (57.4)</td>
</tr>
<tr>
<td></td>
<td>Current</td>
<td>2345 (33.7)</td>
<td>329 (32.9)</td>
</tr>
<tr>
<td></td>
<td>Ex-smoker</td>
<td>793 (11.4)</td>
<td>97 (9.7)</td>
</tr>
<tr>
<td>Categories of peak expiratory flow % predicted</td>
<td>Non-missing</td>
<td>6337 (88.1)</td>
<td>918 (89.0)</td>
</tr>
<tr>
<td></td>
<td>&lt;50%</td>
<td>488 (7.7)</td>
<td>81 (8.8)</td>
</tr>
<tr>
<td></td>
<td>50 - &lt;70%</td>
<td>1527 (24.1)</td>
<td>237 (25.8)</td>
</tr>
<tr>
<td></td>
<td>70 - &lt;80%</td>
<td>1287 (20.3)</td>
<td>186 (20.3)</td>
</tr>
<tr>
<td></td>
<td>≥80</td>
<td>3035 (47.9)</td>
<td>414 (45.1)</td>
</tr>
<tr>
<td>Medication therapy ± SABA (or SAMA)</td>
<td>ICS</td>
<td>921 (12.8)</td>
<td>105 (10.2)</td>
</tr>
<tr>
<td></td>
<td>ICS+LABA (or LAMA)</td>
<td>5498 (76.6)</td>
<td>818 (79.6)</td>
</tr>
<tr>
<td></td>
<td>ICS+LTRA</td>
<td>77 (1.1)</td>
<td>9 (0.9)</td>
</tr>
<tr>
<td>Categories of ICS daily dose consumed (µg)†</td>
<td>ICS+LTRA+ LABA (or LAMA)</td>
<td>&gt;0-160</td>
<td>&gt;160-320</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td></td>
<td></td>
<td>680 (9.5)</td>
<td>95 (9.3)</td>
</tr>
<tr>
<td>&gt;0-160</td>
<td>1733 (24.1)</td>
<td>274 (26.6)</td>
<td>1459 (23.7)</td>
</tr>
<tr>
<td>&gt;160-320</td>
<td>2356 (32.8)</td>
<td>321 (31.2)</td>
<td>2035 (33.0)</td>
</tr>
<tr>
<td>&gt;320-500</td>
<td>1795 (25.0)</td>
<td>248 (24.1)</td>
<td>1547 (25.1)</td>
</tr>
<tr>
<td>&gt;500</td>
<td>1306 (18.2)</td>
<td>187 (18.2)</td>
<td>1119 (18.2)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SABA prescriptions</th>
<th>Non-missing</th>
<th>7178 (99.8)</th>
<th>1,027 (99.6)</th>
<th>6151 (99.8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1356 (18.9)</td>
<td>211 (20.5)</td>
<td>1145 (18.6)</td>
<td></td>
</tr>
<tr>
<td>1-3</td>
<td>2964 (41.3)</td>
<td>416 (40.5)</td>
<td>2548 (41.4)</td>
<td></td>
</tr>
<tr>
<td>4-6</td>
<td>1516 (21.1)</td>
<td>199 (19.4)</td>
<td>1317 (21.4)</td>
<td></td>
</tr>
<tr>
<td>7-9</td>
<td>679 (9.5)</td>
<td>107 (10.4)</td>
<td>572 (9.3)</td>
<td></td>
</tr>
<tr>
<td>10-12</td>
<td>413 (5.8)</td>
<td>67 (6.5)</td>
<td>346 (5.6)</td>
<td></td>
</tr>
<tr>
<td>&gt;12</td>
<td>250 (3.5)</td>
<td>27 (2.6)</td>
<td>223 (3.6)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Acute oral corticosteroid prescriptions¥</th>
<th>0</th>
<th>5613 (78.0)</th>
<th>791 (76.7)</th>
<th>4822 (78.2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥1</td>
<td>1582 (22.0)</td>
<td>240 (23.3)</td>
<td>1342 (21.8)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Antibiotic prescriptions¥</th>
<th>0</th>
<th>5094 (70.8)</th>
<th>726 (70.4)</th>
<th>4368 (70.9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥1</td>
<td>2101 (29.2)</td>
<td>305 (29.6)</td>
<td>1796 (29.1)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Bronchiectasis¶</th>
<th>199 (2.8)</th>
<th>36 (3.5)</th>
<th>163 (2.6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active rhinitis (diagnosis and/or nasal corticosteroids)#</td>
<td>1431 (19.9)</td>
<td>229 (22.2)</td>
<td>1202 (19.5)</td>
</tr>
<tr>
<td>Active oral thrush (diagnosis and/or antifungals)#</td>
<td>276 (3.8)</td>
<td>39 (3.8)</td>
<td>237 (3.8)</td>
</tr>
<tr>
<td>Eczema¶</td>
<td>1955 (27.2)</td>
<td>320 (31.1)</td>
<td>1635 (26.5)</td>
</tr>
</tbody>
</table>

Data are n (%) unless otherwise stated. *Chi-square, t-test, and Mann-Whitney U tests for categorical and interval/ratio variables, respectively. †Fluticasone-equivalent units (based on prescriptions in the year prior to index date). ‡Diagnosis recorded in the year prior to clinical review. §≥1 prescription issued in the year prior to the questionnaire collection. ¥Prescribed during a respiratory consultation.
ICS = inhaled corticosteroid; IQR = interquartile range; LABA = long-acting β-agonist; LAMA = long-acting muscarinic antagonist; LTRA = leukotriene receptor antagonist; SABA = short-acting β-agonist; SAMA = short-acting muscarinic antagonist; SD = standard deviation.
<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Adherence†</th>
<th>Non-fully (n=5801)</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>61.4 (14.5)</td>
<td>59.9 (15.2)</td>
<td>0.001</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>479 (34.4)</td>
<td>1996 (34.4)</td>
<td>1.00</td>
</tr>
<tr>
<td>Body Mass Index (BMI)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Underweight</td>
<td>17 (1.2)</td>
<td>64 (1.1)</td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>395 (28.7)</td>
<td>1501 (26.3)</td>
<td>0.13</td>
</tr>
<tr>
<td>Overweight</td>
<td>503 (36.6)</td>
<td>2062 (36.1)</td>
<td></td>
</tr>
<tr>
<td>Obese</td>
<td>460 (33.5)</td>
<td>2088 (36.5)</td>
<td></td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-missing</td>
<td>1342 (96.4)</td>
<td>5609 (96.7)</td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>786 (58.6)</td>
<td>3028 (54.0)</td>
<td>0.010</td>
</tr>
<tr>
<td>Current</td>
<td>413 (30.8)</td>
<td>1932 (34.4)</td>
<td></td>
</tr>
<tr>
<td>Ex-smoker</td>
<td>143 (10.7)</td>
<td>649 (11.6)</td>
<td></td>
</tr>
<tr>
<td>Peak expiratory flow % predicted</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>78.3 (65.5, 90.6)</td>
<td>79.0 (65.4, 89.8)</td>
<td>0.81</td>
</tr>
<tr>
<td>Medication therapy ±SABA (or SAMA)</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ICS</td>
<td>150 (10.8)</td>
<td>771 (13.3)</td>
<td></td>
</tr>
<tr>
<td>ICS+LABA (or LAMA)</td>
<td>1033 (74.5)</td>
<td>4465 (77.1)</td>
<td></td>
</tr>
<tr>
<td>ICS+LTRA</td>
<td>14 (1.0)</td>
<td>63 (1.1)</td>
<td></td>
</tr>
<tr>
<td>ICS+LTRA+LABA (or LAMA)</td>
<td>190 (13.7)</td>
<td>490 (8.5)</td>
<td></td>
</tr>
<tr>
<td>Acute oral corticosteroid prescriptions*</td>
<td></td>
<td></td>
<td>0.80</td>
</tr>
<tr>
<td>0</td>
<td>1102 (79.2)</td>
<td>4610 (79.5)</td>
<td></td>
</tr>
<tr>
<td>≥1</td>
<td>290 (20.8)</td>
<td>1191 (20.5)</td>
<td></td>
</tr>
<tr>
<td>Bronchiectasis †</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Condition</td>
<td>Adherent Patients (Year 1)</td>
<td>Non-Adherent Patients (Year 2)</td>
<td>P-value</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>---------------------------</td>
<td>-------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Active rhinitis (diagnosis and/or nasal corticosteroids)*</td>
<td>474 (34.1)</td>
<td>1626 (28.0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Active oral thrush (diagnosis and/or antifungals)*</td>
<td>67 (4.8)</td>
<td>209 (3.6)</td>
<td>0.035</td>
</tr>
<tr>
<td>Eczema‡</td>
<td>364 (26.1)</td>
<td>1591 (27.4)</td>
<td>0.33</td>
</tr>
<tr>
<td>Blood eosinophil count</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤400 cells/µL‡</td>
<td>1214 (87.2)</td>
<td>4948 (85.3)</td>
<td>0.067</td>
</tr>
<tr>
<td>&gt;400 cells/µL‡</td>
<td>178 (12.8)</td>
<td>853 (14.7)</td>
<td></td>
</tr>
</tbody>
</table>

Data are n (%) unless otherwise stated. †Based on the medication possession ratio (MPR) and 5611 Medication Adherence Rating Scale (MARS). Adherent patients: >80% MPR and good adherence rating across MARS questionnaire items. *Chi-square, t-test, and Mann-Whitney U tests for categorical and interval/ratio variables, respectively. ¶Diagnosis recorded in the year prior to clinical review. #≥1 prescription issued in the year prior to the questionnaire collection. ¥Prescribed during a respiratory consultation. ‡Two patients in the ≤400 eosinophils /µL cohort had missing adherence data. ICS = inhaled corticosteroid; IQR = interquartile range; LABA = long-acting β-agonist; LAMA = long-acting muscarinic antagonist; LTRA = leukotriene receptor antagonist; SABA = short-acting β-agonist; SAMA = short-acting muscarinic antagonist; SD = standard deviation.
Figure Legends

Figure 1: Study Design. Schematic illustrating the overall study design and patient inclusion criteria. GINA = Global Initiative for Asthma; ICS = inhaled corticosteroids; iHARP = initiative Helping Asthma in Real People; OPCRD = Optimum Patient Care Research Database; QOF = Quality and Outcomes Framework

Figure 2: Patient flow chart. Flow chart showing the selection of the study population from the Optimum Patient Care Database (OPCRD) and the initiative Helping Asthma in Real People (iHARP) database. Abbreviations: COPD = chronic obstructive pulmonary disease; GINA = Global Initiative for Asthma; ICS = inhaled corticosteroids; iHARP = initiative Helping Asthma in Real People; OCS = oral corticosteroids; OPCRD = Optimum Patient Care Research Database; QOF = Quality and Outcomes Framework

Figure 3: Percentage of patients with 0, 1 or 2+ exacerbations by adherence and eosinophil cohort. The proportions of patients within the elevated (>400 cells/µL) and normal blood eosinophil cohorts (≤400 cells/µL) that experienced asthma exacerbations during the baseline year, stratified by adherence to ICS therapy. Severe exacerbations (from combined routine/questionnaire data): occurrence of hospital admissions/emergency department visits or prescriptions of acute courses of oral corticosteroids, in the year prior to the questionnaire collection. P-values were generated by multinomial logistic regression for the risk of having 1 or 2+ exacerbations compared to having no exacerbation. Data is expressed as %.

Figure 4: Percentage of patients with controlled/uncontrolled asthma by adherence and eosinophil cohort. The proportions of patients achieving asthma control, stratified by adherence to ICS therapy, for both the normal (≤400 cells/µL) and elevated (>400 cells/µL) blood eosinophil cohorts are shown. P-values were generated by binomial logistic regression. Data is expressed as %.


40. Malinovschi A, Fonseca JA, Jacinto T, Alving K, Janson C. Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National


